phenytoin has been researched along with Anoxia, Brain in 24 studies
Excerpt | Relevance | Reference |
---|---|---|
" This report describes a near-hanging episode in a patient who subsequently had status epilepticus requiring 40 mg of diazepam and 1,200 mg of phenytoin for control in the prehospital and emergency department stabilization period." | 3.70 | Hanging-induced status epilepticus. ( Pesola, GR; Westfal, RE, 1999) |
"A 75-year-old man suffered a cardiac arrest and severe anoxic encephalopathy." | 1.30 | Periodic complexes, absence-like status and suppression-burst pattern in coma following cardiorespiratory arrest. ( Chemmale, J; Devrajan, VN; Ganji, SS; McDonald, L; Palliyath, S, 1997) |
"In complete global ischemia (cardiac arrest) reperfusion is characterized by an immediate reactive hyperemia followed within 20-30 min by a delayed hypoperfusion state." | 1.29 | [Cerebral protection]. ( Cattaneo, AD, 1993) |
"When phenytoin was administered immediately after the hypoxia, there was no difference between vehicle-injected controls and phenytoin-treated pups." | 1.29 | Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats. ( Hamada, Y; Hattori, H; Hayakawa, T; Maihara, T; Mikawa, H, 1994) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 14 (58.33) | 18.7374 |
1990's | 9 (37.50) | 18.2507 |
2000's | 1 (4.17) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hosseinzadeh, H | 1 |
Sadati, N | 1 |
CELESIA, GG | 1 |
ANDERMANN, F | 1 |
HUGHES, JR | 1 |
SCHLAGENHAUFF, RE | 1 |
Shiu, GK | 1 |
Nemoto, EM | 1 |
Nemmer, J | 1 |
Koller, WC | 1 |
Glatt, SL | 1 |
Perlik, S | 1 |
Huckman, MS | 1 |
Fox, JH | 1 |
Wohns, RN | 1 |
Kerstein, MD | 1 |
Artru, AA | 1 |
Michenfelder, JD | 1 |
Lampley, EC | 1 |
Mishra, OP | 1 |
Graham, E | 1 |
Delivoria-Papadopoulos, M | 1 |
Weber, ML | 1 |
Taylor, CP | 2 |
Domenici, MR | 1 |
Sagratella, S | 1 |
Frank, C | 1 |
Scotti de Carolis, A | 1 |
Cattaneo, AD | 1 |
Hayakawa, T | 1 |
Hamada, Y | 1 |
Maihara, T | 1 |
Hattori, H | 1 |
Mikawa, H | 1 |
Vartanian, MG | 1 |
Cordon, JJ | 1 |
Kupina, NC | 1 |
Schielke, GP | 1 |
Posner, A | 1 |
Raser, KJ | 1 |
Wang, KK | 1 |
Ganji, SS | 1 |
Palliyath, S | 1 |
Chemmale, J | 1 |
Devrajan, VN | 1 |
McDonald, L | 1 |
Toner, CC | 1 |
Stamford, JA | 1 |
Pesola, GR | 1 |
Westfal, RE | 1 |
Aldrete, JA | 1 |
Romo-Salas, F | 1 |
Jankovsky, L | 1 |
Franatovic, Y | 1 |
Moss, G | 4 |
Stein, AA | 3 |
Goto, K | 1 |
Suekawa, M | 1 |
Aburada, M | 1 |
Hosoya, E | 1 |
Heuser, D | 1 |
Guggenberger, H | 1 |
Staunton, C | 1 |
Gordon, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
2 reviews available for phenytoin and Anoxia, Brain
Article | Year |
---|---|
Ionic changes in brain ischaemia and alterations produced by drugs.
Topics: Animals; Biological Transport, Active; Brain Ischemia; Calcium; Calcium Channel Blockers; Cats; Extr | 1985 |
Molecular approaches to the drug enhancement of deteriorated functioning in the aged.
Topics: 1-Propanol; Aging; Amino Alcohols; Amphetamine; Animals; Brain; Cognition; Deoxyribonucleases; DNA; | 1971 |
22 other studies available for phenytoin and Anoxia, Brain
Article | Year |
---|---|
The protective effect of Allium sativum L. clove aqueous and methanolic extracts against hypoxia-induced lethality in mice.
Topics: Animals; Dose-Response Relationship, Drug; Female; Garlic; Hypoxia, Brain; Injections, Intraperitone | 2003 |
SOME OBSERVATIONS ON THE ELECTROGRAPHIC CORRELATES OF THE DECEREBRATE ATTACK.
Topics: Child; Coma; Decerebrate State; Electroencephalography; Epilepsy; Humans; Hypoxia, Brain; Infusions, | 1964 |
THE PERIODICALLY RECURRING FOCAL DISCHARGE.
Topics: Animals; Cerebrovascular Disorders; Child; Drug Therapy; Electrocardiography; Electroencephalography | 1965 |
Dose of thiopental, pentobarbital, and phenytoin for maximal therapeutic effects in cerebral ischemic anoxia.
Topics: Animals; Brain Chemistry; Brain Ischemia; Fatty Acids, Nonesterified; Female; Hypoxia, Brain; Ketami | 1983 |
Cerebellar atrophy demonstrated by computed tomography.
Topics: Adult; Alcoholism; Atrophy; Carcinoma; Cerebellar Diseases; Cerebellar Neoplasms; Cerebral Ventricul | 1981 |
The role of dilantin in the prevention of pulmonary edema associated with cerebral hypoxia.
Topics: Animals; Brain; Disease Models, Animal; Dogs; Female; Hemorrhage; Hypoxia, Brain; Lung; Male; Perfus | 1982 |
Anoxic cerebral potassium accumulation reduced by phenytoin: mechanism of cerebral protection?
Topics: Animals; Cisterna Magna; Dose-Response Relationship, Drug; Heart Arrest; Hypothermia, Induced; Hypox | 1981 |
Neuroprotective effect of phenytoin against in utero hypoxic brain injury in fetal guinea pigs.
Topics: Animals; Cell Membrane; Chromatography, High Pressure Liquid; Female; Fetal Hypoxia; Guinea Pigs; Hy | 1995 |
Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials.
Topics: Action Potentials; Animals; Brain Ischemia; Evoked Potentials; Hippocampus; Hypoxia, Brain; In Vitro | 1994 |
Effects of non-opioid antitussives on hypoxia-induced electrical changes in rat hippocampal slices: a comparative study with anticonvulsant drugs.
Topics: Animals; Anticonvulsants; Antitussive Agents; Cyclopentanes; Dizocilpine Maleate; Electrophysiology; | 1993 |
[Cerebral protection].
Topics: Adrenal Cortex Hormones; Anesthetics; Barbiturates; Benzodiazepines; Brain Ischemia; Calcium Channel | 1993 |
Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Corpus Stria | 1994 |
Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Body Temperature Regulation; Brain Damage, Chronic; Brai | 1996 |
Periodic complexes, absence-like status and suppression-burst pattern in coma following cardiorespiratory arrest.
Topics: Aged; Anticonvulsants; Brain; Coma; Diazepam; Electroencephalography; Epilepsy, Absence; Heart Arres | 1997 |
Sodium channel blockade unmasks two temporally distinct mechanisms of striatal dopamine release during hypoxia/hypoglycaemia in vitro.
Topics: Animals; Dopamine; Electrophysiology; Extracellular Space; Hypoglycemia; Hypoxia, Brain; In Vitro Te | 1997 |
Hanging-induced status epilepticus.
Topics: Adult; Anticonvulsants; Diazepam; Drug Therapy, Combination; Electroencephalography; Emergency Treat | 1999 |
Effect of pretreatment with thiopental and phenytoin on postischemic brain damage in rabbits.
Topics: Animals; Brain Ischemia; Hypoxia, Brain; Phenytoin; Placebos; Rabbits; Thiopental | 1979 |
Cerebral etiology of the acute respiratory distress syndrome: diphenylhydantoin prophylaxis.
Topics: Animals; Bronchial Diseases; Disease Models, Animal; Dogs; Female; Hypoxia, Brain; Lung; Male; Pheny | 1975 |
[Pharmacological study of TJ-8007 (Tsumura-Zokumeito) (I): Protective effects of TJ-8007 against anoxic brain damage].
Topics: Animals; Brain Damage, Chronic; Coma; Drugs, Chinese Herbal; Hypoxia, Brain; Male; Medicine, Chinese | 1987 |
Shock, cerebral hypoxia, and pulmonary vascular control: the centrineurogenic etiology of the respiratory distress syndrome.
Topics: Animals; Animals, Newborn; Brain; Cattle; Cerebrovascular Circulation; Denervation; Dogs; Goats; Hap | 1973 |
Cerebral etiology of the respiratory distress syndrome: universal response, with prevention by unilateral pulmonary denervation.
Topics: Animals; Cattle; Denervation; Dogs; Goats; Haplorhini; Humans; Hypoxia, Brain; Infant, Newborn; Lung | 1973 |
Cerebral etiology of the respiratory distress syndrome: diphenylhydantoin (DPH) prophylaxis.
Topics: Anemia; Animals; Bloodletting; Cardiac Output; Denervation; Dogs; Female; Hypoxia, Brain; Lactates; | 1973 |